When it comes to stocks, thanks to the help of the system, after I feel confident, my communication with investment advisors becomes more assertive.
No matter how much he tried to persuade him, Wu Zhou remained firm and unmoved.
Keep selling plus keep shorting.
In the end, the investment consultant had no choice but to compromise and continue to do what Wu Zhou said.
The next day, as expected, the government issued a lot of good news to boost confidence in the stock market.
Many stocks even surged in the red as a result, but Tesla was not among them.
At the same time, short-selling ETFs are also being bought one after another. This is the best time to buy.
In Wu Zhou in China, Wu Zhou would take a look at these sales and transactions early the next morning.
But after turning around, I had to get busy again.
Medical device companies are still consolidating.
But Aiying Biopharmaceutical Company has sorted everything out.
Talents are also arriving one after another.
In the eyes of the management and employees of Aiying Biotechnology, seeing the arrival of big names one by one, these old employees who are doing research and development with peace of mind are becoming more and more confident.
And after these big guys joined the company, they also found that what they promised before was received as soon as possible.
Just like the 100 million R&D funds, they will be credited immediately upon arrival.
As for the company's work content, they don't need to worry about the social problems of those Lao Shizi. They just need to stay in the laboratory with peace of mind and do the experiments they like.
As for the ordinary researchers and experts below, although many people may not know them, after working for a while, they can feel each other's strength.
Leaders with such strong R&D capabilities have joined the company one after another, so there is no need to worry about future development.
These have gradually increased their confidence.
I even started to look forward to the future. In the future, whether Aiying Biotech will become one of the world's leading pharmaceutical companies in the future.
Biomedicine is very difficult to do.
Although many netizens' comments about Wu Zhou are emotional and may be a bit unpleasant, they are not entirely wrong.
If Wu Zhou is a person without a system, or Wu Zhou has not figured out the system's directional push function.
In the medical field, Wu Zhou will most likely not dare to get involved.
For example, Roche Pharmaceuticals, a top foreign pharmaceutical company, has such a descriptive diagram.
Capital investment of 1000000000 Swiss francs (about the same value as the US dollar)
7000874 working hours (equivalent to 799 years of endless work for one person)
6587 scientific researches
423 scientific researchers
1 drug
This is the drug research and development process of Roche Pharmaceuticals, a top pharmaceutical company, under normal mode.
Generally, early-stage research on a drug involves screening compounds. About 5,000-10,000 compounds are screened out to find a lucky number, such as 250 for preclinical research.
This process usually takes 3-6 years.
About 5 of these 250 compounds can enter clinical research, that is, Phase 1, Phase 2 and Phase 3 clinical trials. This process takes about 6-7 years.
The final step is approval for listing. It is estimated that only one application can be approved, which is a 20% success rate. This process will take about 0.5 to 2 years.
In total, the shortest time is 3+6+0.5=9.5 years.
Judging from these times.
The first item is compound screening. Only less than 5% of nearly 10,000 compounds can advance to the next round.
In other words, 95% of the work time is wasted.
If the system participates in the screening, it will increase sales by 20 times, and even directly select the last drug that can be put on the market in one step.
That’s an efficiency improvement of tens of thousands of times.
Although R&D costs cannot be saved tens of thousands of times.
But saving ten times or a hundred times is not a big problem.
The conclusion is that while others spend tens of billions, Wu Zhou can almost build one with around 1-1 billion.
Of course, the above only exists in theory, and it certainly cannot be carried out in actual practice.
After all, the success rate is unreasonably high and easy to notice.
Of course, Wu Zhou also thought of some compromise methods.
And it is already being implemented.
First, from the perspective of compound screening, some geniuses are born with good luck. Wu Zhou's company happened to be very lucky to recruit him, and it happened that he came to the company's R&D department, and then...
Of course, pure luck will not last long. In the early stage, Wu Zhou could think of every way to accelerate the company's development, but in the later stage, the company must be able to circulate.
Only in this way can it last long and good things can continue to come out.
Of course, the most important thing is that only in this way can Wu Zhou's time be freed up.
Biochemical materials are jokingly called a sinkhole industry by many netizens and students. The main reason is that employment is relatively poor and wages are much lower than in popular industries.
However, wages can only represent a moment, not a lifetime. The importance of these industries is self-evident.
It’s just that the market demand is not that much. In addition, we have a large population. With more people, wages will also fall.
Therefore, after Wu Zhou contacted these universities.
The recruitment process went quite smoothly, and the recent early approval process is already in progress.
In colleges and universities above 211, the starting salary is 10,000+ for undergraduates, 1.5-20,000+ for masters, and 30,000+ for doctoral students.
The salary package offered is about double the current industry price.
Of course, this is for ordinary talents and special talents. This salary is definitely not enough.
The company has a special genius plan, which is modeled after Huawei's 'Genius Plan'.
Provide a sufficient and free R&D environment, R&D funds, and high industry salaries.
Talents are different, and of course their salaries are also different, purely from a salary perspective.
Mainly divided into three levels.
The third level is 700,000-1 million
The second level is 1.3-1.5 million
The first level is 1.8-2 million
Breakthroughs in a field often come from one or two geniuses.
There is also the "Hundred Talents Project" of Wuzhou's company Aiying Biotechnology that is still ongoing. Almost all of them are top scientific research talents. Some of them have not made real achievements yet, but the time has not come yet. , or maybe the research is in the wrong direction and time is wasted.
After all, success depends not only on strength, but also luck.
Wu Zhou will give them ample opportunities and direction, and even find them a suitable partner, so that they can achieve more brilliant results.
With systematic help, the future is still very promising.
Third, it’s the artificial intelligence system.
This is also one of the cutting-edge technologies today.
Artificial intelligence systems have very strong innate advantages, which can greatly help humans improve R&D productivity and greatly improve R&D efficiency and progress.
And as long as there is sufficient data, artificial intelligence can continue to grow through self-learning.
It is almost impossible to use the human brain to retrieve those big data, but for artificial intelligence, these are basic operations.
In this regard, China actually has a very good advantage. In the field of artificial intelligence, there are actually only two players in the world, and we are the other one.
There are actually top experts, top companies, and top products in the field of artificial intelligence in China.
Of course these involve spending money.
Fortunately, Wu Zhou has a lot of money
Of course, the above are still opportunistic and 'step-by-step'.
No matter how to improve efficiency, some processes require so much time.
Therefore, if new drugs are developed from scratch, it is estimated that Wu Zhou’s Aiying Biotech will start to have breakthrough results in ten years.
Still too long.
Still have to think of some new ways.
For example, buy buy buy.
(End of chapter)
